Trevi Therapeutics Inc. Advances in Chronic Cough and Dyskinesia Treatments
Trevi Therapeutics, Inc., a pharmaceutical company headquartered in New Haven, United States, continues to make strides in the healthcare sector with its focus on developing innovative treatments for chronic conditions. The company is primarily engaged in the development of nalbuphine ER, aimed at treating chronic cough in patients suffering from idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia.
As of July 31, 2025, Trevi Therapeutics’ stock closed at $7.33 on the Nasdaq exchange. The company’s market capitalization stands at approximately $919.58 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $8.11 on July 22, 2025, and a low of $2.36 on December 10, 2024. Despite these fluctuations, the company remains a key player in the healthcare sector, particularly in the niche of specialized pharmaceuticals.
Trevi Therapeutics’ current financial metrics indicate a price-to-earnings ratio of -16.281, reflecting the company’s ongoing investment in research and development without immediate profitability. This is not uncommon for companies in the pharmaceutical industry, where substantial upfront costs are often required to bring new therapies to market.
The company’s strategic focus on nalbuphine ER and levodopa-induced dyskinesia positions it uniquely within the healthcare market. By addressing these specific medical needs, Trevi Therapeutics aims to improve the quality of life for patients with chronic conditions, offering new hope where traditional treatments may fall short.
For more detailed information on Trevi Therapeutics’ activities, offerings, and financial performance, stakeholders and interested parties are encouraged to visit their official website at www.trevitherapeutics.com or follow their trading updates on the Nasdaq stock exchange.